ClinicalTrials.gov
public full text
Public Domain
Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.
This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or refractory of ruxolitinib treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.#829483
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML#860127
- Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis#1053084
- Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications#652497
- A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis#1371391
Record · ID 1185458
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive